Published in Antimicrob Agents Chemother on January 19, 2010
Autophagy inhibition for chemosensitization and radiosensitization in cancer: do the preclinical data support this therapeutic strategy? J Pharmacol Exp Ther (2013) 1.24
Malaria in pregnancy. Mediterr J Hematol Infect Dis (2013) 1.11
Implementation of a reference standard and proficiency testing programme by the World Wide Antimalarial Resistance Network (WWARN). Malar J (2010) 1.11
Pharmacokinetics, pharmacodynamics, and allometric scaling of chloroquine in a murine malaria model. Antimicrob Agents Chemother (2011) 1.06
Population pharmacokinetic and pharmacodynamic modeling of amodiaquine and desethylamodiaquine in women with Plasmodium vivax malaria during and after pregnancy. Antimicrob Agents Chemother (2012) 1.04
Azithromycin plus chloroquine: combination therapy for protection against malaria and sexually transmitted infections in pregnancy. Expert Opin Drug Metab Toxicol (2011) 1.01
Artemisinin-naphthoquine combination therapy for uncomplicated pediatric malaria: a pharmacokinetic study. Antimicrob Agents Chemother (2012) 0.98
Pharmacokinetics of piperaquine in pregnant women in Sudan with uncomplicated Plasmodium falciparum malaria. Am J Trop Med Hyg (2012) 0.93
Population pharmacokinetics, tolerability, and safety of dihydroartemisinin-piperaquine and sulfadoxine-pyrimethamine-piperaquine in pregnant and nonpregnant Papua New Guinean women. Antimicrob Agents Chemother (2015) 0.85
Pregnancy-Associated Changes in Pharmacokinetics: A Systematic Review. PLoS Med (2016) 0.83
Safety, tolerability and pharmacokinetic properties of coadministered azithromycin and piperaquine in pregnant Papua New Guinean women. Br J Clin Pharmacol (2016) 0.81
Population pharmacokinetics of a three-day chloroquine treatment in patients with Plasmodium vivax infection on the Thai-Myanmar border. Malar J (2016) 0.75
An HPLC method with diode array detector for the simultaneous quantification of chloroquine and desethylchloroquine in plasma and whole blood samples from Plasmodium vivax patients in Vietnam, using quinine as an internal standard. Biomed Chromatogr (2016) 0.75
Severe falciparum malaria. World Health Organization, Communicable Diseases Cluster. Trans R Soc Trop Med Hyg (2000) 22.12
Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol (2008) 5.34
The importance of modeling interoccasion variability in population pharmacokinetic analyses. J Pharmacokinet Biopharm (1993) 3.66
Intermittent presumptive treatment for malaria. PLoS Med (2005) 3.36
Clinical pharmacokinetics of antimalarial drugs. Clin Pharmacokinet (1985) 3.03
Disposition of chloroquine in man after single intravenous and oral doses. Br J Clin Pharmacol (1983) 2.59
Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications. Clin Pharmacokinet (1996) 2.33
Distribution of chloroquine and its metabolite desethyl-chloroquine in human blood cells and its implication for the quantitative determination of these compounds in serum and plasma. J Chromatogr (1983) 2.28
Antimalarial drugs and pregnancy: safety, pharmacokinetics, and pharmacovigilance. Lancet Infect Dis (2007) 1.74
In vitro activities of piperaquine and other 4-aminoquinolines against clinical isolates of Plasmodium falciparum in Cameroon. Antimicrob Agents Chemother (2003) 1.72
The single dose kinetics of chloroquine and its major metabolite desethylchloroquine in healthy subjects. Eur J Clin Pharmacol (1984) 1.65
Pharmacokinetics and efficacy of piperaquine and chloroquine in Melanesian children with uncomplicated malaria. Antimicrob Agents Chemother (2007) 1.64
Cardiovascular toxicity and distribution kinetics of intravenous chloroquine. Br J Clin Pharmacol (1986) 1.30
Alterations in drug disposition during pregnancy: implications for drug therapy. Expert Opin Drug Metab Toxicol (2007) 1.25
Pharmacokinetics of sequential and simultaneous treatment with the combination chloroquine and sulfadoxine-pyrimethamine in acute uncomplicated Plasmodium falciparum malaria in the Philippines. Trop Med Int Health (2002) 1.16
In vitro metabolism of chloroquine: identification of CYP2C8, CYP3A4, and CYP2D6 as the main isoforms catalyzing N-desethylchloroquine formation. Drug Metab Dispos (2003) 1.12
Pharmacokinetics of chloroquine in Thais: plasma and red-cell concentrations following an intravenous infusion to healthy subjects and patients with Plasmodium vivax malaria. Br J Clin Pharmacol (1988) 1.11
The disposition of chloroquine in healthy Nigerians after single intravenous and oral doses. Br J Clin Pharmacol (1987) 1.11
Using pharmacokinetics to predict the effects of pregnancy and maternal-infant transfer of drugs during lactation. Expert Opin Drug Metab Toxicol (2006) 1.11
Pharmacokinetic properties of sulfadoxine-pyrimethamine in pregnant women. Antimicrob Agents Chemother (2009) 1.08
Cytochrome P450 2C8 and CYP3A4/5 are involved in chloroquine metabolism in human liver microsomes. Arch Pharm Res (2003) 1.06
Comparison of the pharmacokinetics of chloroquine after single intravenous and intramuscular administration in healthy Africans. Br J Clin Pharmacol (1986) 1.03
The pharmacokinetics of three multiple dose regimens of chloroquine: implications for malaria chemoprophylaxis. Br J Clin Pharmacol (1995) 1.02
Chloroquine pharmacokinetics in pregnant and nonpregnant women with vivax malaria. Eur J Clin Pharmacol (2008) 1.00
Apparent dose-dependence of chloroquine pharmacokinetics due to limited assay sensitivity and short sampling times. Eur J Clin Pharmacol (1987) 1.00
The pharmacokinetics of chloroquine in healthy Thai subjects and patients with Plasmodium vivax malaria. Br J Clin Pharmacol (1994) 0.95
Whole-blood single-dose kinetics of chloroquine and desethylchloroquine in Africans. Ther Drug Monit (1986) 0.90
Chloroquine blood concentrations and malaria prophylaxis in Tanzanian women during the second and third trimesters of pregnancy. Eur J Clin Pharmacol (1997) 0.81
Pharmacokinetics of chloroquine and some of its metabolites in healthy volunteers: a single dose study. J Clin Pharmacol (1989) 0.79
Evidence for increased metabolism of chloroquine during the early third trimester of human pregnancy. Trop Med Int Health (2004) 0.79
Comparison of the partitioning in vitro of chloroquine and its desethyl metabolites between the erythrocytes and plasma of healthy subjects and those with falciparum malaria. Afr J Med Med Sci (1989) 0.78
Plasmodium knowlesi malaria in humans is widely distributed and potentially life threatening. Clin Infect Dis (2008) 9.87
A trial of combination antimalarial therapies in children from Papua New Guinea. N Engl J Med (2008) 4.77
Analysis of Plasmodium falciparum diversity in natural infections by deep sequencing. Nature (2012) 4.37
Genome-wide and fine-resolution association analysis of malaria in West Africa. Nat Genet (2009) 4.30
Mass treatment with single-dose azithromycin for yaws. N Engl J Med (2015) 3.84
Global emm type distribution of group A streptococci: systematic review and implications for vaccine development. Lancet Infect Dis (2009) 3.51
Population pharmacokinetics of piperaquine in adults and children with uncomplicated falciparum or vivax malaria. Br J Clin Pharmacol (2004) 3.48
Efficacy and safety of dihydroartemisinin-piperaquine (Artekin) in Cambodian children and adults with uncomplicated falciparum malaria. Clin Infect Dis (2002) 3.40
Reported reasons for not using a mosquito net when one is available: a review of the published literature. Malar J (2011) 3.16
The peopling of the Pacific from a bacterial perspective. Science (2009) 3.14
Clinical and laboratory features of human Plasmodium knowlesi infection. Clin Infect Dis (2009) 2.92
Oxidative stress in malaria parasite-infected erythrocytes: host-parasite interactions. Int J Parasitol (2004) 2.92
Association of early interferon-gamma production with immunity to clinical malaria: a longitudinal study among Papua New Guinean children. Clin Infect Dis (2008) 2.80
Piperaquine: a resurgent antimalarial drug. Drugs (2005) 2.80
The risk of malarial infections and disease in Papua New Guinean children. Am J Trop Med Hyg (2007) 2.72
Common infections in diabetes: pathogenesis, management and relationship to glycaemic control. Diabetes Metab Res Rev (2007) 2.50
Immunoglobulin G subclass-specific responses against Plasmodium falciparum merozoite antigens are associated with control of parasitemia and protection from symptomatic illness. Infect Immun (2009) 2.22
Comparison of three antigen detection methods for diagnosis and therapeutic monitoring of malaria: a field study from southern Vietnam. Trop Med Int Health (2002) 2.22
Serum alanine aminotransferase, metabolic syndrome, and cardiovascular disease in an Australian population. Am J Gastroenterol (2009) 2.20
Glycemic exposure is associated with reduced pulmonary function in type 2 diabetes: the Fremantle Diabetes Study. Diabetes Care (2004) 2.09
Is self-monitoring of blood glucose appropriate for all type 2 diabetic patients? The Fremantle Diabetes Study. Diabetes Care (2006) 2.09
Geographical structure of diversity and differences between symptomatic and asymptomatic infections for Plasmodium falciparum vaccine candidate AMA1. Infect Immun (2003) 2.02
Molecular evidence for the localization of Plasmodium falciparum immature gametocytes in bone marrow. Blood (2013) 2.01
Effects of a high-fat meal on the relative oral bioavailability of piperaquine. Antimicrob Agents Chemother (2005) 2.00
Artemisinin-based combination therapies for uncomplicated malaria. Med J Aust (2005) 1.98
Evaluation of Plasmodium vivax genotyping markers for molecular monitoring in clinical trials. J Infect Dis (2009) 1.95
Changing patterns of Plasmodium blood-stage infections in the Wosera region of Papua New Guinea monitored by light microscopy and high throughput PCR diagnosis. Am J Trop Med Hyg (2006) 1.93
Rise in malaria incidence rates in South Africa: a small-area spatial analysis of variation in time trends. Am J Epidemiol (2002) 1.88
Differential patterns of infection and disease with P. falciparum and P. vivax in young Papua New Guinean children. PLoS One (2010) 1.87
Safety evaluation of fixed combination piperaquine plus dihydroartemisinin (Artekin) in Cambodian children and adults with malaria. Br J Clin Pharmacol (2004) 1.84
Parvovirus B19 infection contributes to severe anemia in young children in Papua New Guinea. J Infect Dis (2006) 1.82
Improved laboratory capacity is required to respond better to future cholera outbreaks in Papua New Guinea. Western Pac Surveill Response J (2012) 1.79
Association between naturally acquired antibodies to erythrocyte-binding antigens of Plasmodium falciparum and protection from malaria and high-density parasitemia. Clin Infect Dis (2010) 1.79
Malaria in pregnancy in the Asia-Pacific region. Lancet Infect Dis (2012) 1.78
Glucuronidation of dihydroartemisinin in vivo and by human liver microsomes and expressed UDP-glucuronosyltransferases. Drug Metab Dispos (2002) 1.70
Identification and prioritization of merozoite antigens as targets of protective human immunity to Plasmodium falciparum malaria for vaccine and biomarker development. J Immunol (2013) 1.68
Strategies for detection of Plasmodium species gametocytes. PLoS One (2013) 1.67
A sub-microscopic gametocyte reservoir can sustain malaria transmission. PLoS One (2011) 1.67
Comparison of the Framingham and United Kingdom Prospective Diabetes Study cardiovascular risk equations in Australian patients with type 2 diabetes from the Fremantle Diabetes Study. Med J Aust (2009) 1.67
Comparison of Plasmodium falciparum allelic frequency distribution in different endemic settings by high-resolution genotyping. Malar J (2009) 1.67
Pharmacokinetics and efficacy of piperaquine and chloroquine in Melanesian children with uncomplicated malaria. Antimicrob Agents Chemother (2007) 1.64
Clinical immunity to malaria. Curr Mol Med (2006) 1.63
Naturally acquired Duffy-binding protein-specific binding inhibitory antibodies confer protection from blood-stage Plasmodium vivax infection. Proc Natl Acad Sci U S A (2008) 1.63
Comparison of diagnostic methods for the detection and quantification of the four sympatric Plasmodium species in field samples from Papua New Guinea. Malar J (2010) 1.60
Complement activation and the resulting placental vascular insufficiency drives fetal growth restriction associated with placental malaria. Cell Host Microbe (2013) 1.57
Features and prognosis of severe malaria caused by Plasmodium falciparum, Plasmodium vivax and mixed Plasmodium species in Papua New Guinean children. PLoS One (2011) 1.55
Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine. Am J Trop Med Hyg (2014) 1.51
The pharmacokinetic properties of intramuscular artesunate and rectal dihydroartemisinin in uncomplicated falciparum malaria. Br J Clin Pharmacol (2002) 1.48
Multiplicity and diversity of Plasmodium vivax infections in a highly endemic region in Papua New Guinea. PLoS Negl Trop Dis (2011) 1.47
Multilocus haplotypes reveal variable levels of diversity and population structure of Plasmodium falciparum in Papua New Guinea, a region of intense perennial transmission. Malar J (2010) 1.47
Ownership and usage of mosquito nets after four years of large-scale free distribution in Papua New Guinea. Malar J (2012) 1.45
Reduced Plasmodium vivax erythrocyte infection in PNG Duffy-negative heterozygotes. PLoS One (2007) 1.45
Serum carboxymethyllysine concentrations are reduced in diabetic men with abdominal aortic aneurysms: Health In Men Study. J Vasc Surg (2009) 1.41
Effect of a pharmaceutical care program on vascular risk factors in type 2 diabetes: the Fremantle Diabetes Study. Diabetes Care (2005) 1.41
Peripheral arterial disease and risk of cardiac death in type 2 diabetes: the Fremantle Diabetes Study. Diabetes Care (2006) 1.40
The current status and potential role of laboratory testing to prevent transfusion-transmitted malaria. Transfus Med Rev (2005) 1.36
Loss-of-function mutations in IGSF1 cause an X-linked syndrome of central hypothyroidism and testicular enlargement. Nat Genet (2012) 1.34
Force of infection is key to understanding the epidemiology of Plasmodium falciparum malaria in Papua New Guinean children. Proc Natl Acad Sci U S A (2012) 1.33
A comparison of the sensitivities of detection of Plasmodium falciparum gametocytes by magnetic fractionation, thick blood film microscopy, and RT-PCR. Malar J (2009) 1.32
Population pharmacokinetics of artemether, lumefantrine, and their respective metabolites in Papua New Guinean children with uncomplicated malaria. Antimicrob Agents Chemother (2011) 1.32
Measurement of piperaquine in plasma by liquid chromatography with ultraviolet absorbance detection. J Chromatogr B Analyt Technol Biomed Life Sci (2003) 1.30
Clinical and parasitological response to oral chloroquine and primaquine in uncomplicated human Plasmodium knowlesi infections. Malar J (2010) 1.29
Enhanced detection of gametocytes by magnetic deposition microscopy predicts higher potential for Plasmodium falciparum transmission. Malar J (2008) 1.28
Diabetes education and knowledge in patients with type 2 diabetes from the community: the Fremantle Diabetes Study. J Diabetes Complications (2003) 1.27
Evidence that the erythrocyte invasion ligand PfRh2 is a target of protective immunity against Plasmodium falciparum malaria. J Immunol (2010) 1.26
B-vitamins reduce the long-term risk of depression after stroke: The VITATOPS-DEP trial. Ann Neurol (2010) 1.25
Desbutyl-lumefantrine is a metabolite of lumefantrine with potent in vitro antimalarial activity that may influence artemether-lumefantrine treatment outcome. Antimicrob Agents Chemother (2011) 1.24
How much remains undetected? Probability of molecular detection of human Plasmodia in the field. PLoS One (2011) 1.23